STOCK TITAN

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call scheduled for March 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter 2022 financial results and provide a business update. The call will be accessible via telephone and an audio webcast. The company focuses on developing innovative pharmaceuticals aimed at reducing healthcare costs and improving patient outcomes, specifically targeting outpatient care for acute conditions such as heart failure and infectious diseases.

Positive
  • Focus on developing innovative products to reduce healthcare costs.
  • Targeting outpatient care for acute conditions like heart failure.
Negative
  • None.

Management to host conference call and webcast at 4:30 p.m. ET

BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 22, 2023, to discuss the financial results for the fourth quarter 2022 and provide a business update.

Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13736270.

To access the new Call me™ feature, which avoids having to wait for an operator, click here.

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7578
pkelleher@lifesciadvisors.com 



FAQ

When is the scPharmaceuticals conference call for fourth quarter 2022 results?

The conference call is scheduled for March 22, 2023, at 4:30 p.m. ET.

What is the main focus of scPharmaceuticals?

scPharmaceuticals focuses on developing and commercializing products that reduce healthcare costs and improve patient outcomes.

How can I access the scPharmaceuticals conference call?

The call can be accessed by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with conference code 13736270.

What is the stock symbol for scPharmaceuticals?

The stock symbol for scPharmaceuticals is SCPH.

scPharmaceuticals Inc.

NASDAQ:SCPH

SCPH Rankings

SCPH Latest News

SCPH Stock Data

177.14M
35.58M
10.68%
81.64%
11.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BURLINGTON